Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
2,649
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
stocks
ASX energy share undervalued ahead of earnings
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,311.90 | 125.80 | 1.37% |
| CAC 40 | 8,632.37 | 18.55 | 0.22% |
| DAX 40 | 26,170.90 | 169.59 | 0.65% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,891.92 | 34.22 | 0.32% |
| HKSE | 25,852.92 | 156.48 | -0.60% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,957.53 | 202.63 | 0.32% |
| NZX 50 Index | 13,903.46 | 128.53 | 0.93% |
| S&P 500 | 7,600.50 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,145.80 | 122.80 | 1.36% |
| SSE Composite Index | 3,822.28 | 12.62 | 0.33% |